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Concise report
Early response to anti-TNF predicts long-term
outcomes including sustained remission:
an analysis of the BSRBR-RA
Philip D. H. Hamann 1, John D. Pauling2, Neil McHugh 2,
Kimme Hyrich 3,5 and Gavin Shaddick4; and the BSRBR-RA
Contributors Group
Abstract
Objective. To identify different trajectories of disease activity in patients with RA following initiation of a first
anti-TNF.
Methods. Patients with RA starting their first anti-TNF between 2001 and 2013 were selected from the British
Society for Rheumatology Biologics Register for RA. Six-monthly DAS28-ESR scores were used to identify trajecto-
ries of disease activity using latent class modelling. Data were included for six follow-ups after registration (approxi-
mately 3 years). Subgroup analysis examined changes in disease activity profiles over time.
Results. A total of 14 436 patients with RA starting their first anti-TNF were enrolled between 2001 and 2013
(13 115 between 2001 and 2008, 1321 between 2010 and 2013). The mean number of DAS28-ESR scores was
3.5/patient (S.D. 2.1), with a mean of 184.9 days (S.D. 69.9) between scores. The DAS28-ESR nadir was achieved
within 250 days of commencing anti-TNF, although apparent trajectory divergence emerged by first 6-monthly
follow-up at 180 days. Four distinct response trajectories comprised the most stable model. Most patients fitted
into ‘modest’ (7986 patients; 55.3%) or ‘substantial’ (4676 patients; 32.4%) response trajectories. Of the remainder,
1254 (8.7%) and 520 (3.6%) fitted ‘maximal’ and ‘minimal’ response trajectories, respectively. There was a signifi-
cant (P<0.01) increase in proportion achieving ‘maximal’ response between 2001–2008 and 2010–2013.
Conclusion. This is the largest study to identify long-term response trajectories with anti-TNF. By 6months, longer-term
trajectory profiles of DAS28 could already be identified, with many patients identified earlier. The majority of patients had
persistent moderate response, equivalent to maintained DAS28-ESR moderate disease activity. The maximal response tra-
jectory (equivalent to sustained DAS2-ESR remission) was only achieved by approximately one-third of patients.
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Introduction
Over the past 20 years, anti-TNF medications have rad-
ically changed the therapeutic landscape of RA. Treat-
to-target (T2T) approaches aim to rapidly achieve a
state of remission with regular reviews and medication
changes and are associated with improved outcomes
and reduced radiographic damage [1]. Because RA is a
chronic disease, remission should be maintained over
time (sustained remission) and is associated with
improved outcomes and reduced mortality in early arth-
ritis cohorts [2, 3]. While extensive evidence supports
Rheumatology key messages
. Sustained remission is uncommon in biologic-naı¨ve patients taking anti-TNF for RA.
. Six-month DAS28-ESR scores are representative of long-term outcomes in biologic-naı¨ve RA patients starting anti-TNF.
1Musculoskeletal Research Unit, University of Bristol, Bristol,
2Department of Pharmacy and Pharmacology, University of Bath,
Bath, 3Division of Musculoskeletal and Dermatological Sciences,
University of Manchester, Manchester, 4Department of
Mathematics, University of Exeter, Exeter and 5National Institute of
Health Research Musculoskeletal Biomedical Research Centre,
Manchester University NHS Foundation Trust, Manchester
Academic Health Science, Manchester, UK
Submitted 27 February 2019; accepted 18 September 2019
Correspondence to: Philip Hamann, Musculoskeletal Research Unit,
University of Bristol, Learning and Research Building, Southmead
Road, Bristol BS10 5NB, UK. E-mail: Philip.hamann@bristol.ac.uk
C
L
IN
IC
A
L
S
C
IE
N
C
E
VC The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use,
distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Rheumatology
Rheumatology 2019;0:1–6
doi:10.1093/rheumatology/kez518
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
atology/advance-article-abstract/doi/10.1093/rheum
atology/kez518/5622925 by U
niversity of Bristol Library user on 09 January 2020
anti-TNF use, most studies report single time point out-
comes and studies of sustained response to anti-TNF
are sparse [4]. Contributing to challenges in establishing
an evidence base for sustained remission is the difficulty
in achieving a standardized definition of the outcome,
in terms of both which outcome measures to use,
and the minimum duration required to be classed as
‘sustained’ [5].
T2T approaches use a threshold (remission) as the
‘target’ of treatment. However, most clinical outcome
measures have a continuous scale, and in a clinical
setting the use of pre-defined thresholds to define sus-
tained remission can pose challenges for patients strad-
dling remission thresholds. For these patients, evidence
would suggest further intensification of treatment.
However, they may feel well, and potential additional clin-
ical improvements in symptoms may only be slight [6].
Latent class modelling methods are an alternative way
of assessing longitudinal disease activity and identifying
different trajectories of disease activity within these data
without requiring a pre-set threshold. Such methodology
uses multiple longitudinal measures of disease activity
to identify mean trajectories [7]. This allows accurate
representation of longitudinal outcomes of a cohort of
patients, without artificial dichotomization of data, and
could predict future outcomes given a patient’s prior tra-
jectory. Such modelling techniques have previously
been used to identify different classes of response to
T2T strategies in an early arthritis cohort and in RA
patients taking abatacept [8–10].
This study aims to identify different trajectories of dis-
ease activity in patients with RA following initiation of a
first anti-TNF.
Methods
This is an analysis of patients receiving anti-TNF who
are part of the British Society for Rheumatology
Biologics Register for RA (BSRBR-RA). The BSRBR-RA,
launched in 2001, is a national, prospective, longitudinal,
observational study examining long-term effectiveness
and safety of biologic agents in patients with RA in the
UK. Ethical approval was obtained from the Multicentre
Research Ethics Committee for the North-West of
England. All patients enrolled provided written informed
consent. The methods of the BSRBR-RA have been
described previously [11]. Biologic use in England and
Wales is directed by NICE guidance, which requires
patients to have persistent high disease activity (DAS28
score of >5.1) despite treatment with at least two con-
ventional synthetic DMARDs (csDMARDs), one of which
should be methotrexate (unless contraindicated) [12].
Therefore, the BSRBR-RA is a cohort enriched for high
baseline disease activity, and does not include early
arthritis patients.
Patient data are collected 6-monthly for the first
3 years following enrolment. Thereafter data collection
occurs annually. Only the first 3 years of data were
included for each patient to ensure sufficient data
granularity to identify temporal changes in disease activ-
ity. All patients starting their first anti-TNF between 2001
and 2013 were included, to allow 3 years of data collec-
tion up to a data censor date of 30 September 2016.
There was a pause in new enrolments for anti-TNF in
the BSRBR-RA between 2008 and 2010, so this was
chosen as the point to split the dataset to allow evalu-
ation of changes in responses to anti-TNF treatment
over time (enrolments between 2001 and 2008 were
included in one subgroup, and enrolments between
2010 and 2013 included in the second subgroup). This
also coincided with the publication of the first EULAR
recommendations for the management of RA that incor-
porated T2T recommendations, which is likely to have
influenced clinical practice subsequently [6]. Elapsed
time was calculated in days from the date on the base-
line enrolment form and subsequent DAS28-ESR meas-
urements. Data were censored at time of switching to
another anti-TNF or biologic agent, or discontinuation of
anti-TNF.
Data were examined to ensure ‘missingness’ occurred
at random and bootstrapped multiple imputation (using
five datasets) was used for missing data. Latent class
mixed modelling (LCMM; R package) was used to model
DAS28-ESR scores over time and identify different tra-
jectories [7]. The lcmm function was used and a linear
link function was selected, which deployed a standard
linear mixed model (using the same estimation as the
hlme function within the lcmm package). DAS28-ESR
scores were modelled over time and grouped by patient.
The lowest Bayesian Information criterion (BIC) was
used to identified the model with the number of trajecto-
ries that best fit the data of the whole cohort [13].
Because of the difference in subgroup sizes, BIC values
were used to identify the most stable model in the
smaller subgroup (2010–2013) and this model was then
applied to the larger subgroup (2001–2008) to allow sub-
group comparisons. Posterior probabilities were exam-
ined to investigate the reliability of the selected model
[14]. The graphical representations of all the trajectories
inferred by the LCMM for all the imputed datasets were
manually checked (by P.H.) to ensure trajectories identi-
fied were similar between imputations.
Results
A total of 14 436 patients with RA starting their first anti-
TNF were enrolled between 2001 and 2013. Of these,
13 115 were enrolled between 2001 and 2008, and 1321
between 2010 and 2013. The baseline characteristics of
the patients are outlined in Table 1. The mean (S.D.)
number of DAS28-ESR scores per patients was 3.5
(2.1), with a mean (S.D.) of 184.9 (69.9) days between
scores, and 198.2 (75.3) days between enrolment and
first recorded DAS28-ESR.
Mean BIC was calculated for two- (219 136), three-
(219 063), four- (219 032) and five-class (219 038)
LCMM models in the whole cohort (2001–2013). The
four-class model had the lowest mean BIC representing
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the most stable model. The most stable LCMM model
for the 2010–2013 subgroup was the two-class model
(BIC values: two-class: 18 585; three-class: 18 600;
four-class: 18 617). Because LCMM does not adhere to
predefined DAS28-ESR disease activity thresholds, the
trajectories for the four-class model were labelled max-
imal/substantial/modest/minimal, and maximal and min-
imal for the two-class model, to respectively represent
the greatest to least reduction in DAS28-ESR from
baseline. Graphical representation showed four distinct
trajectories of response for the whole cohort, and two
trajectories for the 2001–2008 and 2010–2013 sub-
groups, with the greatest reduction in DAS28-ESR
achieved by 250 days after starting anti-TNF in all
groups (Fig. 1).
Posterior probabilities for the two-class model show a
high likelihood of correct trajectory classification
(Supplementary Table S1, available at Rheumatology on-
line). For the four-class model, posterior probabilities for
the maximal and minimal trajectory classification were
high (>0.7) [7]. However, the posterior probabilities for
the substantial and modest response trajectories were
more ambiguous, with values of 0.62 and 0.64, respect-
ively. The maximal response trajectory was uncommon
with only 1254 patients (8.7%) achieving this outcome.
The majority of patients achieved either a modest (7986
patients; 55.3%) or a substantial response (4676
patients; 32.4%). Only 520 patients (3.6%) were classi-
fied as minimal responders. There was a significant (v2
P<0.01) improvement in maximal response in the two-
class model from 4382 patients (33%) in the 2001–2008
subgroup to 502 patients (38%) in the 2010–2013 sub-
groups (Fig. 1).
Discussion
This study is the first to apply LCMM to evaluate pat-
terns of treatment response in RA patients with high dis-
ease activity commencing their first anti-TNF therapy.
Different trajectory patterns are identifiable and emerge
within a few months of treatment instigation. These data
support current NICE guidance for assessing response
to anti-TNF at 6 months (180 days), by which point differ-
ent trajectories of response are clearly defined [12]. All
trajectories follow a similar profile, with an initial rapid
change in DAS28-ESR followed by a plateau phase
where disease activity scores achieved by 250 days re-
main stable. Our results show that responses seen at
6 months are representative of long-term outcomes and
that it may be possible to identify long-term responses
to anti-TNF earlier than 6 months.
Other studies have shown that responses to anti-TNF
can be seen earlier than 6 months [15, 16]. The graphical
representation of the trajectories from this study (Fig. 1)
suggest that this may be the case in these data as well,
although confirmatory DAS28-ESR data are sparse be-
fore 6 months (Supplementary Fig. S1, available a
Rheumatology online).
Unlike other studies we did not observe differences in
rate of response (such as a rapid and gradual response
curve), or a ‘U-shaped’ response trajectory representing
a secondary non-response [8, 10]. The lack of a U-
shaped secondary non-response trajectory may be due
to the infrequency of secondary non-response in the
BSRBR-RA dataset, or that a 6-month data collection is
insufficiently frequent to identify secondary non-
response before switching occurs (and hence censoring
from the dataset). Examination of the trajectory plots
TABLE 1 Baseline characteristics and change in patient characteristics at start of first anti-TNF recorded in the BSRBR-
RA over-time
Variable Whole cohort
(2001–2013)
2001-2008
subgroup
2010-2013
subgroup
P-valuea
Number 14 436 13 115 1321 NA
Female, % 76.3 76.3 75.7 0.6
Age, (S.D.), years 56.0 (12.3) 56.0 (12.2) 56.3 (12.7) 0.4
DAS28-ESR, range 0–10 (S.D.) 6.5 (1.0) 6.6 (1.0) 6.0 (1.0) <0.01
Swollen joint count, range 0–28 (S.D.) 11.1 (6.2) 11.4 (6.2) 8.7 (5.2) <0.01
Tender joint count, range 0–28 (S.D.) 15.5 (7.4) 15.6 (7.4) 14.6 (7.5) <0.01
Patient global assessment, range 0–100 mm (S.D.) 72.5 (19.8) 72.5 (19.8) 72.2 (19.5) 0.6
ESR, (S.D.), mm/h 44.7(28.2) 46.0 (28.3) 29.6 (22.8) <0.01
HAQ, range 0–3 (S.D.) 2.0 (0.6) 2.0 (0.6) 1.6 (0.7) <0.01
BMI, (S.D.), kg/m2 27.2 (8.1) 27.0 (6.8) 29.6 (17.1) <0.01
Disease duration, mean, median (S.D.), years 12.7, 11.0 (9.6) 13.0, 11.0 (9.6) 9.6, 6.0 (9.5) <0.01
Time from first rheumatology consult to biologics,
mean, median (S.D.), years
12.0, 10.0 (9.0) 12.2, 10.0 (8.9) 9.5, 6.0 (9.0) <0.01
Baseline MTX, n (%) 8176 (56.6) 7332 (55.9) 844 (63.9) <0.01
Current smoker, n (%) 3108 (21.8) 2861 (22.0) 247 (19.9) 0.03a
Ever smoked, n (%) 5368 (37.7) 4922 (37.8) 446 (36.0)
Never smoked, n (%) 5778 (40.5) 5232 (40.2) 546 (44.1)
Unless otherwise specified, numbers shown are mean values. aComparing subgroups using unpaired t test, except gender and
smoking data, which used v2. BSRBR-RA: British Society for Rheumatology Biologics Register for RA; NA: not applicable.
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(Fig. 1) shows a small rebound at approximately
6 months in maximal and substantial response trajecto-
ries, which may be evidence of early secondary non-
responders, who subsequently switch drug before the
next data collection point. The absence of ‘rapid’ or
‘gradual’ responder curves may be because these tra-
jectories truly do not exist in the dataset, or that an in-
sufficient frequency of assessments misses this
response trajectory.
The minimal response trajectory in the four-class
model is likely to comprise patients from the earlier
years of the BSRBR-RA when there were fewer options
for switching biologic, and/or patients who may have re-
fractory disease in which clinician and patient may have
decided further improvements in disease activity are un-
likely with alternative disease modifying agents [17]. The
minimal response trajectory could be explained by the
fact that trajectories are smoothed group-level trajecto-
ries and do not show all the linked individual data points
for each patient. An individual patient’s disease activity
will fluctuate around the smoothed mean trajectory over
time and temporary improvements may encourage a
clinician and patient to continue the anti-TNF, which
with hindsight can be seen to be ineffective on average.
There may also be other undocumented factors that
may make a clinician and patient opt to remain on a
treatment despite ongoing disease activity. Analyses of
factors associated with the attainment of different levels
of disease activity were not undertaken, but they have
been examined in depth in other work by our group and
others [4].
The number of patients achieving the maximal or sub-
stantial response trajectory in the four-class model is
similar to that of other studies investigating sustained
FIG. 1 Illustrative trajectory plots of response to anti-TNF over time for two- and four-class trajectory models
(A) The four-class model had the lowest BIC for the overall dataset and is shown here. The two-class model was
most stable for the 2010–2013 subgroup. To allow comparison between 2001–2008 and 2010–2013 subgroups, the
two-class graphical illustrations are shown in (B) and (C). X: maximal response is seen in all trajectories by 250 days.
Grey shading represents 95% CI.
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remission, and highlights that the majority of patients
taking anti-TNFs agents in this cohort (and others) have
persistent moderate disease activity [4]. Even when
examining outcomes from patients commenced on anti-
TNF after 2010, the majority of patients do not achieve
sustained responses in the remission or low disease ac-
tivity range. These data demonstrate that despite
changes in clinical practice and widely accepted T2T
recommendations, the clinical reality of outcomes of RA
patients taking anti-TNF is more modest than may be
perceived [18]. EULAR recommendations suggest a tar-
get of remission or low disease activity should be a real-
istic goal for the majority of RA patients, and advise that
if these targets are not obtained, treatment should be
intensified or switched as soon as is possible.
Furthermore, these recommendations are based upon
the EULAR and ACR agreed Boolean, or simplified or
clinical DAI definition of remission, which is even more
stringent than the DAS28-ESR definition of remission
used in this study [19, 20]. The results of this study
show that while the EULAR recommendations are sound
and robustly evidence-based, achieving the target of
sustained remission or low disease activity may remain
aspirational for the majority of patients who require anti-
TNF in the UK and elsewhere, most of whom have al-
ready shown resistance to csDMARDs.
This study has limitations. It is an observational study,
and as such, causality cannot be inferred. While data
examined are from a cross-section of clinical sites across
the UK and the BSRBR-RA has broad inclusion criteria, it
is possible recruitment bias may have occurred. Data col-
lection occurred 6-monthly. While separation of trajecto-
ries appears to occur early after anti-TNF commencement
and there are data for this period (Supplementary Fig. S1,
available at Rheumatology online), it is limited, and there
is no formal data collection before 6 months. Therefore, it
remains possible the earlier separation seen is an artefact
of trajectory smoothing within the statistical software. It
should also be noted that the BSRBR-RA only collects
data at 6-monthly intervals meaning that any additional
clinic visit data between these 6-monthly intervals is not
captured. While the four-class trajectory model is the
most stable model identified for the cohort as a whole,
there is still a degree of uncertainty about the class as-
signment relating to the substantial and modest
trajectories.
This is the largest study of response trajectories to
anti-TNF in patients with RA and shows that the goal of
achieving sustained remission or low disease activity
(maximal and substantial response trajectories) is sel-
dom achieved, with the majority of patients only achiev-
ing a sustained moderate disease activity (modest
response trajectory).
Different trajectories of response identified at
6 months are indicative of future outcomes, with max-
imal therapeutic benefit identified 250 days after start-
ing anti-TNF. Early divergence of trajectories suggests
assessment of anti-TNF efficacy may be possible before
the currently recommended 6-month review, which
would enable patients with suboptimal response to
switch treatments earlier, improving outcomes and
minimizing cost of inefficacious treatments. Further work
is necessary to identify if the results identified for anti-
TNF agents are common across all DMARDs, and for
patients who have switched to second- or third-line bio-
logic agents.
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